Back to Gene
NOG gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

NOG gene

The NOG gene provides instructions for making the noggin protein, which is essential for proper bone and joint development.

Normal Function

The NOG gene provides instructions for making a protein called noggin. This protein is involved in the development of many body tissues, including nerve tissue, muscles, and bones. Noggin's role in bone development makes it important for proper joint formation.

Noggin interacts with members of a group of proteins called bone morphogenetic proteins (BMPs). These proteins help control the development of bone and other tissues. In order to begin these developmental processes, BMPs attach (bind) to other proteins called receptors, and this binding stimulates specific cellular processes. The noggin protein regulates the activity of certain BMPs by attaching to them and blocking them from binding to the receptor, which leads to a decrease in BMP signaling.

Health Conditions Related to Genetic Changes

Tarsal-carpal coalition syndrome

Several mutations in the NOG gene have been identified in people with a condition called tarsal-carpal coalition syndrome. This condition is characterized by fusion of the individual bones in the wrists (the carpal bones) and in the ankles (the tarsal bones) as well as fusion at the joints between the bones that make up each finger and toe (symphalangism). Symphalangism makes the fingers and toes stiff and difficult to bend.

This condition is caused by mutations in the NOG gene that change single protein building blocks (amino acids) in the noggin protein. These mutations alter the structure or stability of noggin, impair the transport of noggin out of the cell, or reduce the protein's ability to bind to BMPs, resulting in a reduction of functional noggin protein. With decreased noggin function, BMPs abnormally stimulate bone formation in joint areas, where there should be no bone, causing the bone fusions seen in people with tarsal-carpal coalition syndrome.

Other disorders

Several other bone-related disorders are caused by mutations in the NOG gene. These gene mutations change single protein building blocks (amino acids) in the noggin protein:

  • Proximal symphalangism: Characterized by fusion at the joints between the bones in the fingers and toes, particularly at the joint at the base of the digit. Other signs include abnormally short middle fingers, webbed toes, and hearing loss due to fusion of the bones in the ears (stapes fixation).
  • Multiple synostoses syndrome 1: Characterized by symphalangism and characteristic facial features, such as a broad nose and thin lips. Affected individuals can have fusion of the bones in the hands, feet, hips, and upper part of the spine (cervical vertebrae).
  • Stapes ankylosis with broad thumb and toes (Teunissen-Cremers syndrome): Individuals have hearing loss due to stapes fixation, farsightedness, and broad thumbs and big toes.
  • Brachydactyly type B2: Characterized by short fingers and toes because the middle bone of the digit or the bone that forms the tip of the digit is abnormally small or absent.

As in tarsal-carpal coalition syndrome, the NOG gene mutations that cause these conditions reduce the amount of functional noggin protein. Because of a shared genetic cause and overlapping features, researchers have suggested that these conditions represent a spectrum of related conditions referred to as NOG-related-symphalangism spectrum disorder (NOG-SSD).

Frequently Asked Questions

Diagnosis typically starts with a detailed physical exam showing stiff fingers or toes and limited joint motion. Imaging studies—X‑ray, CT, or MRI—can reveal bone fusions in the wrists, ankles, or digits. Genetic testing for NOG mutations confirms the diagnosis.
Treatment ranges from conservative measures such as physical therapy and pain management to surgical release or correction of fused joints. Outcomes vary; many patients achieve improved mobility and pain relief, but some residual stiffness may persist. Early intervention often yields better functional results.
Because NOG mutations are autosomal dominant, a first‑degree relative has a 50% chance of carrying the same mutation. Genetic testing can identify carriers, who may be asymptomatic or develop mild joint stiffness later in life. Knowing carrier status helps with family planning and early monitoring.
Yes, certain missense mutations that severely disrupt noggin’s ability to bind BMPs tend to cause more extensive bone fusions and greater joint stiffness. Conversely, mutations that only modestly reduce noggin function may result in milder symptoms. Genetic analysis can sometimes predict the clinical severity, guiding prognosis and management.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA